A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ME1100 Inhalation Solution (Arbekacin Inhalation Solution) Administered to Healthy Volunteers

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ME1100 Inhalation Solution (Arbekacin Inhalation Solution) Administered to Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2014

At a glance

  • Drugs Arbekacin (Primary)
  • Indications Bacterial infections; Nosocomial pneumonia; Various toxicities
  • Focus Adverse reactions
  • Sponsors Meiji Seika Pharma
  • Most Recent Events

    • 09 Sep 2014 Results of a pooled analysis of this trial and a single dose trial were presented at presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 11 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top